IP Library Granted Patent US 10,751,533
Granted Patent B2
US 10,751,533 · App. 15/505,053 · Granted Aug 25, 2020

Regulation of autonomic control of bladder voiding after a complete spinal cord injury

Inventors: Victor Reggie Edgerton (Los Angeles, CA); Parag Gad (Woodland Hills, CA); Roland R. Roy (Playa Vista, CA); Yury P. Gerasimenko (Los Angeles, CA); Daniel C. Lu (Los Angeles, CA); Hui Zhong (Monterey Park, CA)
Assignee: The Regents of the University of California
A61N1/36007A61H3/00A61K31/475A61K31/496A61K31/506A61K45/06A61N1/3606A61N1/36014A61N1/36071A63B21/06A63B22/02A61N1/36157A61N1/36171A61N1/36175
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,751,533
App. No.
15/505,053
Granted
Aug 25, 2020
Kind
B2
Abstract

In various embodiments methods and devices are provided for regulating bladder function in a subject after a spinal cord and/or brain injury. In certain embodiments the methods comprise applying a pattern of electrical stimulation to the Lumbosacral spinal cord at a frequency and intensity sufficient to initiate micturition and/or to improve the amount of bladder emptying. In certain embodiments the electrical stimulation is at a frequency and intensity sufficient to improve the amount of bladder emptying (e.g., to provide at least 30% emptying or at least 40% emptying, or at least 50% emptying, or at least 60% emptying, or at least 70% emptying, or at least 80% emptying, or at least 90% emptying, or at least 95% emptying.

Claims (46)

1. A method of improving bladder function in a subject with impaired bladder control, said method comprising:

applying a pattern of epidural electrical stimulation or transcutaneous electrical stimulation to a lumbosacral spinal cord of said subject at a frequency and intensity that excites neural networks within said lumbosacral spinal cord sufficient to react to a second signal comprising the introduction of physical training and/or supraspinal input to induce bladder emptying and/or to improve the amount of bladder emptying.

2. The method of claim 1 , wherein said subject has a spinal cord or brain injury or a neurological injury or illness.

3. The method of claim 1 , wherein said electrical stimulation is at a frequency and intensity sufficient to cause at least 30% bladder emptying or to improve bladder emptying by at least 30% in response to said second signal.

4. The method of claim 1 , wherein bladder emptying is initiated within 10 seconds of initiation of electrical stimulation.

5. The method of claim 1 , wherein said electrical stimulation is over a region of the spinal cord comprising or consisting of the region from L1 to S5 or from L1 to S3, or from L1 to S1, or from L2 to S1.

6. The method of claim 1 , wherein said electrical stimulation comprises epidural electrical stimulation of the spinal cord.

7. The method of claim 6 , wherein:

said epidural electrical stimulation of the spinal cord is at an amplitude ranging from about 0.01 mA up to about 50 mA or to about 30 mA, or from about 0.1 mA to about 20 mA, or from about 0.1 mA to about 15 mA or to about 10 mA; and/or

said epidural electrical stimulation of the spinal cord comprises pulses having a pulse width ranging from about 1 μs to about 1 ms.

8. The method of claim 6 , wherein said epidural electrical stimulation of the spinal cord is applied via a permanently implanted electrode array.

9. The method of claim 1 , wherein said electrical stimulation comprises transcutaneous electrical stimulation.

10. The method of claim 9 , wherein:

said transcutaneous stimulation is at an amplitude ranging from 10 mA up to about 300 mA, or up to about 150 mA, or up to about 100 mA, or from about 20 mA to about 300 mA, or up to about 150 mA or up to about 100 mA, or from about 20 mA or from about 30 mA, or from about 40 mA up to about 50 mA, or up to about 60 mA, or up to about 70 mA or up to about 80 mA, or up to about 100 mA, or up to about 150 mA, or up to about 200 mA, or up to about 250 mA, or up to about 300 mA; and/or

said transcutaneous stimulation pulse width ranges from about 0.5 up to about 5 ms.

11. The method of claim 9 , wherein said transcutaneous electrical stimulation is superimposed on a high frequency carrier signal.

12. The method of claim 11 , wherein:

said high frequency carrier signal ranges from 3 kHz, or about 5 kHz, or about 8 kHz up to about 80 kHz, or up to about 50 kHz, or up to about 40 kHz, or up to about 30 kHz, or up to about 20 kHz, or up to about 15 kHz; and/or

said high frequency carrier amplitude ranges up to about 300 mA.

13. The method of claim 1 , wherein:

said method does not comprise direct stimulation of the pelvic nerve; and/or

said method does not comprise transection of the pudendal nerve; and/or

said method does not comprise direct stimulation of the sacral nerve; and/or

said method does not comprise direct stimulation of the anterior sacral nerve.

14. The method of claim 1 , wherein said method further comprises physical training of said subject.

15. The method of claim 14 , wherein:

said physical training comprises movement of a region of the torso and/or legs of the subject; and/or

said physical training comprises a change in postural position; and/or

said physical training comprises a locomotor activity associated with standing and/or stepping and/or sitting; and/or

said training comprises training against a resistance; and/or

said training is robotically facilitated; and/or

said training utilizes a treadmill and/or an exoskeleton, and/or a prosthesis.

16. The method of claim 1 , wherein said method further comprises administration of a drug selected from the group consisting of a serotonergic drug, a dopaminergic drug, a noradrenergic drug, a GABAergic drug, and a glycinergic drug.

17. The method of claim 16 , wherein said drug is selected from the group consisting of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine (S15535), N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridinyl)cyclohexanecarboxamide (WAY 100.635), quipazine, strychnine, ketanserin, 4-amino-(6-chloro-2-pyridyl)-1 piperidine hydrochloride (SR 57227A), Ondanesetron, buspirone, methoxamine, prazosin, clonidine, yohimbine, 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol (SKF-81297), 7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol (SCH-23390), quinpirole, and eticlopride.

18. The method of claim 2 , wherein said subject has a spinal cord injury.

19. The method of claim 18 , wherein said spinal cord injury is clinically classified as motor complete.

20. A method of training a subject having a spinal cord and/or brain injury, or other pathology causing bladder dysfunction to improve initiation of micturition and/or to improve the amount of bladder emptying, said method comprising:

administering to said subject repeated electrical stimulation training sessions according to claim 1 .

21. A system for controlling and/or improving bladder function in a mammal, said system comprising a transcutaneous electrode and/or an epidural electrode electrically coupled to an electrical stimulator configured to deliver transcutaneous electrical stimulation of the lumbosacral spinal cord through a transcutaneous electrode and/or epidural electrical stimulation of the lumbosacral spinal cord through an epidural electrode according to the method of claim 1 .

22. The method of claim 1 , wherein said subject has a spinal cord injury causing paralysis and said improving bladder function comprises restoring bladder function by applying a pattern of electrical stimulation to the spinal cord of said subject.

23. The method of claim 1 , wherein said subject has a spinal cord injury causing paralysis and said improving bladder function comprises enabling locomotor-related spinal neuronal circuits by epidural stimulation.

24. The method of claim 1 , wherein said subject has a spinal cord injury causing paralysis and said improving bladder function comprises:

placing electrodes epidurally or transcutaneously on the dorsum of the spinal cord; and

energizing the electrodes with a frequency-dependent stimulation pattern that is therapeutically effective.

25. The method of claim 1 , wherein said subject has a pathology leading to poor bladder function.

26. The method of claim 1 , wherein said method further comprises training utilizing repeated bouts of electrical stimulation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2020
From: EDGERTON, VICTOR R.; GAD, PARAG; ROY, ROLAND R.; GERASIMENKO, YURY P.; LU, DANIEL C.; ZHONG, HUI
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 051983/0439 →
CONFIRMATORY LICENSE Recorded Apr 10, 2017
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042204/0051 →
Continuity (2)
Provisional Application 62040334 · Aug 21, 2014
Related Publication 20170274209A1 · Sep 28, 2017
Cited By (15)
US 12,268,878 US 12,311,169 US 12,357,828 US 12,397,156 US 12,415,079 US 12,434,068 US 12,478,777 US 12,551,714 US 12,613,624 US 12,623,070 US 12,623,080 US 12,649,062 US 12,708,772 US 12,708,775 US 12,722,002